#South Korea #Seoul #Hugel #Letybo #Revolax

Hugel Reports Significant Q3 Growth

Hugel Inc., a prominent player in the medical aesthetics sector based in South Korea, has recently released its consolidated financial results for the third quarter of 2025. The company showcased a remarkable performance, achieving a staggering net sales figure of KRW 105.9 billion. This impressive growth trajectory has been attributed to robust international sales of its signature products, including botulinum toxin and hyaluronic acid dermal fillers, as well as a thriving cosmetics division. Notably, this marks the second consecutive quarter in which Hugel has surpassed the KRW 100 billion mark in net sales, reflecting its ongoing growth momentum in a competitive market.

Financial Highlights

In the latest report, Hugel announced that its operating profit reached KRW 47.4 billion, while net income stood at KRW 38 billion. The company maintained a strong profitability margin, with a remarkable 77% gross profit and 45% operating profit, indicating effective cost management and market positioning. The solid performance highlights Hugel's capability to navigate competitive pressures while sustaining high operational efficiency.

Global Market Performance

Key Markets and Product Breakdown

A significant 80% of Hugel's total net sales in botulinum toxin and dermal fillers stemmed from exports, underscoring the company's global reach. Sales for the company's botulinum toxin, marketed globally as Letybo, contributed KRW 60.2 billion, whereas its hyaluronic acid fillers, known as Revolax, generated KRW 30.2 billion. Additionally, the cosmetics brands WELLAGE and BYRYZN BR recorded combined sales of KRW 14.9 billion, reflecting a 65% increase compared to the same quarter last year.

The top four markets for botulinum toxin products— the United States, China, Europe, and Brazil— accounted for approximately 45% of the overall net sales. Carrie Strom, President and Global CEO of Hugel, expressed optimism about the sales performance, stating, "We are very encouraged by the growth in the major toxin markets, as we expect these regions to remain significant drivers for our business moving forward."

About Hugel

Founded in 2001, Hugel is a recognized leader in the medical aesthetics industry, focusing on the development and manufacturing of injectables specifically designed for skin rejuvenation. The company’s portfolio encompasses botulinum toxin, hyaluronic acid fillers, skin boosters, as well as absorbable sutures and diverse cosmetic products. Hugel is committed to advancing the medical aesthetics field through rigorous research, extensive training programs, and active participation in industry forums. With operations in around 70 countries and nine global subsidiaries spanning the U.S., Australia, Canada, Taiwan, China, Hong Kong, Singapore, and Thailand, Hugel is poised for continued growth and expansion in the global markets.

In conclusion, Hugel’s Q3 2025 performance underscores its strategic positioning in the medical aesthetics sector and highlights its potential for sustained growth amid rising competition. The company's commitment to quality and innovation remains at the forefront as it navigates the evolving landscape of the global beauty and wellness market.